Los ntawm Cocer Peptides 
1 month ago
Tag nrho cov kab lus thiab cov ntaub ntawv ntawm cov khoom lag luam muab rau ntawm lub vev xaib no tsuas yog rau cov ntaub ntawv tshaj tawm kev tshaj tawm thiab cov hom phiaj kev kawm.
Cov khoom muab rau hauv lub vev xaib no yog npaj tshwj xeeb rau kev tshawb fawb hauv vitro. Kev tshawb fawb hauv vitro (Latin: * hauv iav *, lub ntsiab lus hauv iav) yog ua los ntawm tib neeg lub cev. Cov khoom no tsis yog tshuaj, tsis tau txais kev pom zoo los ntawm US Food and Drug Administration (FDA), thiab yuav tsum tsis txhob siv los tiv thaiv, kho, lossis kho txhua yam mob, kab mob, lossis mob. Nws raug txwv nruj raws li txoj cai los qhia cov khoom no rau hauv tib neeg lossis tsiaj lub cev hauv txhua daim ntawv.
Txheej txheem cej luam
Tirzepatid, ib qho tshuaj tshiab, tau txais kev saib xyuas tseem ceeb hauv kev kho mob ntshav qab zib. Nws yog lub ntiaj teb thawj dual agonist ntawm glucagon-zoo li peptide-1 (GLP-1) receptor thiab cov piam thaj-dependent insulinotropic polypeptide (GIP) receptor. Los ntawm nws cov txheej txheem tshwj xeeb ntawm kev ua, nws ua raws li cov txiaj ntsig ntuj ntawm GLP-1 thiab GIP, muab cov kev xaiv tshiab rau kev tswj ntshav qabzib.
Daim duab 1 Mechanisms of action of Tirzepatid in the human body.
Mechanism ntawm Action
Kev tswj hwm ntawm insulin thiab glucagon secretion: Tirzepatid nce insulin secretion thiab txo glucagon tso tawm raws li cov piam thaj-dependant. Thaum cov ntshav qabzib nce siab, Tirzepatid ua rau pancreatic beta hlwb kom tso cov tshuaj insulin ntau dua, yog li ua kom cov piam thaj nce ntxiv thiab siv thiab txo cov ntshav qabzib; Nws kuj tseem inhibits glucagon secretion, txo cov ntshav qabzib hauv siab, ntxiv stabilizing cov ntshav qabzib. Qhov kev tswj xyuas ob-pronged no pab tswj cov ntshav qabzib sib npaug, txo qis kev yoo mov thiab postprandial ntshav qabzib.
Txhawb kom satiety thiab poob phaus: Cov tshuaj no tuaj yeem txhawb kev satiety, ua rau cov neeg mob txo cov zaub mov noj thiab yog li poob phaus. Kev poob phaus yog qhov tseem ceeb rau cov neeg mob ntshav qab zib hom 2, vim kev rog rog feem ntau cuam tshuam nrog insulin tsis kam. Los ntawm kev txo qhov hnyav, Tirzepatid pab txhim kho insulin rhiab heev, ua rau lub cev teb rau insulin ntau dua thiab yog li tswj cov ntshav qabzib zoo dua. Tsis tas li ntawd, kev poob phaus yuav pab txo qis kev pheej hmoo ntawm cov teeb meem xws li kab mob plawv hauv cov neeg mob ntshav qab zib.
Kev ncua lub plab zom mov: Tirzepatid ncua lub plab zom mov, ua kom lub sijhawm cov zaub mov tseem nyob hauv plab thiab ua kom nws nkag mus rau hauv cov hnyuv me, yog li tiv thaiv kev nce siab hauv cov ntshav qab zib. Cov nyhuv no pab tswj cov ntshav qab zib kom ruaj khov, tshwj xeeb tshaj yog los ntawm kev tswj cov ntshav qab zib tom qab peaks, tsim kom muaj txiaj ntsig zoo rau kev tswj ntshav qab zib kom ruaj khov.
Txhim kho cov cim metabolic: Ntxiv nrog rau nws cov teebmeem ntawm cov ntshav qab zib thiab qhov hnyav, Tirzepatid kuj pom muaj txiaj ntsig zoo hauv kev txhim kho qib lipid thiab lwm cov cim metabolic. Cov kev tshawb fawb soj ntsuam qhia tau hais tias nws pab txo qis lipoprotein tsawg (LDL) cov roj cholesterol thiab triglyceride, txhim kho kev noj qab haus huv tag nrho thiab txo qis kev pheej hmoo ntawm cov kab mob plawv hauv cov neeg mob ntshav qab zib.
Daim ntawv thov
Hauv kev ua tiav SURPASS thiab SURMOUNT loj-qib Phase III kev tshawb fawb soj ntsuam, Tirzepatid tau pom tias muaj kev tswj hwm cov ntshav qabzib zoo dua. Piv nrog rau cov placebo, Tirzepatid txo qis hemoglobin A1c (HbA1c) qib thaum tseem qhia txog kev poob phaus zoo. Nws txoj kev ua tau zoo tshaj qhov tam sim no pom zoo GLP-1 receptor agonists. Hauv qee qhov kev sim, cov neeg mob kho nrog Tirzepatid tau ntsib kev txo qis hauv HbA1c ntau dua thiab ua kom poob phaus, qhia meej meej tias nws ua tau zoo thiab zoo tshaj hauv kev tswj glycemic thiab tswj qhov hnyav.
Kev Kho Mob Ntshav Qab Zib Hom 2: Raws li kev noj haus thiab kev tawm dag zog, Tirzepatid muab kev kho mob zoo rau cov neeg mob ntshav qab zib hom 2. Txawm hais tias siv raws li kev kho mob monotherapy lossis ua ke nrog lwm cov tshuaj tiv thaiv kab mob ntshav qab zib, Tirzepatid ua rau cov neeg mob ntshav qabzib tswj tau zoo.
Xaus
Hauv cov ntsiab lus, Tirzepatid qhia tau zoo hauv kev tswj ntshav qabzib vim nws cov txheej txheem tshwj xeeb ntawm kev ua haujlwm thiab kev ua tau zoo hauv kev sim tshuaj. Nws tsis tsuas yog txo qis cov piam thaj hauv cov ntshav, tab sis kuj tseem ua lub luag haujlwm zoo hauv kev tswj qhov hnyav thiab txhim kho cov cim metabolic.
Qhov chaw
[1] Sood A, Kaur P, Syed O, et al. Kev hloov pauv kev kho mob ntshav qab zib: nthuav tawm tirzepatide lub peev xwm hauv kev tswj glycemic thiab dhau [J]. Kws tshuaj ntsuam xyuas ntawm Clinical Pharmacology, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, et al. Tirzepatid: Dual Glucose-dependent Insulinotropic Polypeptide thiab Glucagon-zoo li Peptide-1 Agonist rau Kev Tswj Xyuas Hom 2 Mob ntshav qab zib mellitus [J]. American Journal of Therapeutics, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, et al. Kev Qhia Txog Tirzepatid, Kev Kho Mob Ob Lub Hom Phiaj rau Mob Ntshav Qab Zib thiab Kev rog [J]. International Journal of Innovative Research & Growth, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda VP, Ajabiya J, Teli D, et al. Tirzepatid, Lub Sijhawm Tshiab ntawm Kev Kho Mob Ob Lub Hom Phiaj rau Mob Ntshav Qab Zib thiab Kev rog: Mini-Review [J]. Molecules, 2022,27(13).DOI:10.3390/molecules27134315.
[5] Forzano I, Varzideh F, Avvisato R, et al. Tirzepatid: A Systematic Update[J]. International Journal of Molecular Sciences, 2022,23(23).DOI:10.3390/ijms232314631.
Cov khoom muaj rau kev tshawb fawb siv nkaus xwb:
